National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD 20892, USA.
Nat Rev Rheumatol. 2010 Aug;6(8):477-85. doi: 10.1038/nrrheum.2010.103. Epub 2010 Jul 6.
Spondyloarthritis (SpA) refers to a spectrum of immune-mediated inflammatory diseases with overlapping features, which differ from other types of inflammatory arthritis in genetic predisposition, pathogenesis and outcome. SpA frequently involves the axial skeleton, and can result in abnormal bone formation with eventual ankylosis of the spine, resulting in substantial disability. SpA often begins as an 'undifferentiated' disease, the presentation of which differs in children and adults; most notably, spinal involvement is uncommon, while hip arthritis and enthesitis are frequently seen in juvenile-onset disease. Currently, the classification of SpA in adults and children is approached differently. Using the International League of Associations for Rheumatology (ILAR) system for juvenile idiopathic arthritis, most childhood SpA is classified as enthesitis-related arthritis. However, in contrast to adult SpA classification, the presence of, or a family history of, psoriasis dictates a separate category of juvenile idiopathic arthritis. More importantly, the ILAR system does not specifically recognize the presence of axial disease in juvenile SpA. Resolution of these issues will improve communication and the transitioning of patients from pediatric to adult clinics, will facilitate research in genetics and pathogenesis, and will be particularly important in the evaluation of tumor necrosis factor inhibitors and other biologic agents for early, axial SpA.
脊柱关节炎(SpA)是一组具有重叠特征的免疫介导性炎症性疾病,其在遗传易感性、发病机制和预后方面与其他类型的炎性关节炎不同。SpA 常累及中轴骨骼,可导致异常骨形成,最终脊柱融合,导致严重残疾。SpA 常起始为“未分化”疾病,其在儿童和成人中的表现不同;最明显的是,脊柱受累不常见,而髋关节关节炎和附着点炎在幼年发病的疾病中常见。目前,成人和儿童的 SpA 分类方法不同。根据国际风湿病联盟(ILAR)的幼年特发性关节炎系统,大多数儿童 SpA 被归类为附着点相关关节炎。然而,与成人 SpA 分类不同的是,银屑病的存在或家族史决定了幼年特发性关节炎的一个单独类别。更重要的是,ILAR 系统并未专门识别幼年 SpA 中存在的中轴疾病。解决这些问题将改善沟通,促进患者从儿科诊所到成人诊所的过渡,有助于遗传和发病机制的研究,对于评估早期中轴 SpA 的肿瘤坏死因子抑制剂和其他生物制剂尤其重要。